Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021; Massachusetts Medical Society; Volume: 385; Issue: 12 Linguagem: Inglês
10.1056/nejmoa2107322
ISSN1533-4406
AutoresOliver Sartor, Johann S. de Bono, Kim N., Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Luke T. Nordquist, Nitin Vaishampayan, Ghassan El‐Haddad, Chandler H. Park, Tomasz M. Beer, Alison Armour, Wendy J. Pérez-Contreras, Michelle DeSilvio, Euloge Kpamegan, Germo Gericke, Richard A. Messmann, Michael J. Morris, Bernd J. Krause,
Tópico(s)Mass Spectrometry Techniques and Applications
ResumoMetastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 (177Lu)–PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment.
Referência(s)